NeoGenomics (NEO) Morgan Stanley 22nd Annual Global Healthcare Conference summary

Key accomplishments and transformation

• Achieved a turnaround from losses to profitability, with double-digit growth and raised guidance.

• Focused on expanding cancer testing access in community settings, addressing 85% of cancer patients.

• Maintained a comprehensive portfolio, differentiating from competitors by offering end-to-end solutions.

Product innovation and growth drivers

• Launched key NGS products, with two major launches planned for 2025, including a pan-cancer liquid biopsy (PanTrace) and a large tumor panel.

• NGS mix and new products are driving AUP growth, with NGS expected to exceed 50% of clinical revenue in coming years.

• Expanded commercial team by 35% to increase reach in community oncology and rural practices.

Commercial strategy and operational efficiency

• Leveraged leadership in Heme to expand into new accounts and drive adoption of the broader NGS portfolio.

• Investing in AI tools and digital transformation to improve sales force effectiveness and customer integration.

• Digital initiatives include consolidating LIMS systems, launching a new portal, and expanding EMR interfaces to 250 sites in 2024.